Calendar Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Market Closed - Hong Kong S.E. 01:38:20 26/04/2024 pm IST 5-day change 1st Jan Change
1.34 HKD -1.47% Intraday chart for Ascletis Pharma Inc. +4.69% -8.22%

Chart calendar Ascletis Pharma Inc.

3b0d602d88a16.jEawYqBl24D2_uBm2CxmQn3BQfZfdHqJLSGjQemuywg._nHoD_oQmeayi6kViWovLhmpdaMlLTzgbkPHeIXJvWm7LNQ0-VCM-cWTuQ~da0b9091cb15231df42e1f4171a58d3c

Upcoming events on Ascletis Pharma Inc.

19/08/2024 Q2 2024 Earnings Release (Projected)
24/03/2025 Q4 2024 Earnings Release (Projected)
25/08/2025 Q2 2025 Earnings Release (Projected)
31/03/2026 Q4 2025 Earnings Release (Projected)

Past events on Ascletis Pharma Inc.

25/03/2024 Q4 2023 Earnings Release
10/03/2024 American Academy of Dermatology Meeting
12/11/2023 American Association for the Study of Liver Diseases Conference - Poster ID: 2401-C
12/11/2023 American Association for the Study of Liver Diseases Conference - Poster ID: 5052-C
08/11/2023 International Workshop on HBV Cure
10/10/2023 European Academy of Dermatology and Venereology Congress - Poster #P0053
21/08/2023 Q2 2023 Earnings Release
23/07/2023 International AIDS Society Conference
20/03/2023 Q4 2022 Earnings Release
20/02/2023 Retroviruses and Opportunistic Infections Conference
16/02/2023 Asian Pacific Association for the Study of the Liver Meeting
06/11/2022 American Association for the Study of Liver Diseases Meeting - Abstract 2314
22/08/2022 Interim 2022 Earnings Release
25/06/2022 12:45 pm European Association for the Study of the Liver International Liver Congress - Abstract Number: OS09
25/06/2022 11:45 am International Liver Congress - Abstract No: OS091
08/04/2022 10:30 pm American Association of Cancer Research Meeting - Abstract #5529
08/04/2022 10:30 pm American Association of Cancer Research Meeting - Abstract #5466
21/03/2022 FY 2021 Earnings Release
15/11/2021 11:00 pm American Association for the Study of Liver Diseases Meeting - #LO12
14/11/2021 08:30 pm AASLD The Liver Meeting

Annual results

Fiscal PeriodDecember 2018 2019 2020 2021 2022 2023
Net sales
Million CNY
Released
Forecast
Spread
166
166
-0.04%
173
166
4.34%
35,0
198
-82.31%
76,9
68,0
13.03%
54,1
157
-65.59%
56,6
54,6
3.71%
EBITDA
Million CNY
Released
Forecast
Spread
-133
-97,5
-36.14%
-189
-251
24.72%
-258
-32,0
-706.18%
-217
-173
-25.46%
-374
-169
-120.63%
-290
-199
-45.78%
EBIT
Million CNY
Released
Forecast
Spread
-145
-100
-44.37%
-211
-206
-2.29%
-285
-44,9
-534.71%
-247
-187
-32.2%
-404
-190
-113.04%
-309
-221
-39.95%
Earnings before Tax (EBT)
Million CNY
Released
Forecast
Spread
-19,9
-14,0
-41.93%
-96,0
-127
24.52%
-209
-29,2
-616.63%
-199
-167
-18.95%
-315
-148
-112.57%
-145
-92,3
-56.75%
Net income
Million CNY
Released
Forecast
Spread
-7,26
-2,00
-262.9%
-96,0
-127
24.52%
-209
-29,2
-616.63%
-199
-167
-18.95%
-315
-148
-112.57%
-145
-130
-11.62%
EPS
CNY
Released
Forecast
Spread
0,00
0,00
-
-0,09
-0,12
20.87%
-0,20
-0,03
-570.67%
-0,18
-0,16
-13.31%
-0,29
-0,14
-113.73%
-0,13
-0,12
-12.88%
Announcement Date24/03/1924/03/2030/03/2121/03/2219/03/2325/03/24

Quarterly results

Fiscal PeriodDecember 2019 S1 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales
Million CNY
Released
Forecast
Spread
75,4
145
-48.1%
98,0
93,5
4.89%
31,8
81,0
-60.69%
3,17
128
-97.52%
36,5
26,3
39.02%
40,3
33,5
20.35%
38,2
50,8
-24.74%
15,9
42,4
-62.57%
46,5
46,5
0.01%
10,1
20,7
-51.26%

0,00


0,00

EBIT
Million CNY
Released
Forecast
Spread
























-80,3
-73,8
-8.78%
-229
-148
-54.24%

-177


-194

EPS
CNY
Released
Forecast
Spread



-0,05
-0,05
7.4%
-0,05
-0,01
-394%
-0,15
-0,01
-1418%
-0,10
-0,07
-44.14%
-0,08
-0,09
10.67%
-0,08
-0,07
-15.71%
-0,21
-0,15
-39.07%
-0,02
-0,02
24%
-0,12
-0,07
-70.71%

-0,12


-0,14

Announcement Date29/08/1924/03/2028/08/2030/03/2126/08/2121/03/2222/08/2219/03/2322/08/2325/03/24--

Net sales - Quarter - Rate of surprise

Quarterly earnings - Rate of surprise

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 1672 Stock
  4. Calendar Ascletis Pharma Inc.